Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-flow nasal cannula hydrogen gas for acute respiratory distress syndrome
jRCTs062220003Recruiting
- Sponsor
- Japan Society for Emergency Medicine
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of Molecular hydrogen in acute respiratory distress syndrome (ARDS), sponsored by Japan Society for Emergency Medicine. Primary endpoint: Incidence of death and invasive mechanical ventilation within 10 days. Started Jan 2023; status: recruiting.
02
Drugs
Molecular hydrogen
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on jRCTs062220003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs062220003.